HER2/neu antisense targeting of human breast carcinoma

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

p185^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

1989 • 672 citations

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

2000 • 460 citations

p185neu expression in human lung adenocarcinomas predicts shortened survival.

1990 • 440 citations

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1985 • 408 citations

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1998 • 380 citations

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1997 • 344 citations

Role of HER2 gene overexpression in breast carcinoma

2000 • 306 citations

Single-Chain Antibody-Mediated Intracellular Retention of ErbB-2 Impairs Neu Differentiation Factor and Epidermal Growth Factor Signaling

1995 • 300 citations

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1991 • 296 citations

Does antisense exist?

1995 • 257 citations

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

1986 • 231 citations

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

1991 • 208 citations

Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

1999 • 174 citations

Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene

1984 • 158 citations

Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells.

1996 • 149 citations

Apoptosis: An Overview of the Process and Its Relevance in Disease

1997 • 121 citations

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

1993 • 119 citations

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

1995 • 114 citations

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1997 • 112 citations

Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.

2000 • 107 citations

Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cellsin vitro

1997 • 80 citations

ErbB Receptor Activation, Cell Morphology Changes, and Apoptosis Induced by Anti-Her2 Monoclonal Antibodies

1996 • 38 citations

Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease1

2000 • 30 citations

Antisense Oligonucleotides Specific for the HER2/neu Oncogene Inhibit the Growth of Human Breast Carcinoma Cells That Overexpress HER2/neu

1998 • 26 citations

Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells

1998 • 25 citations

Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents

1999 • 25 citations

Fas-Signaling and Effects on Receptor Tyrosine Kinase Signal Transduction in Human Breast Epithelial Cells

1997 • 24 citations

Cited By (0)

Loading...